Keryx Biopharma (KERX) Reports Q1 Loss of 13c/Share, Misses by 1c

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) reported Q1 EPS of ($0.13), $0.01 worse than the analyst estimate of ($0.12).

For earnings history and earnings-related data on Keryx Biopharmaceuticals, Inc. (KERX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group
• Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'